SavedAdd your journal

Journals / Turkish archives of pediatrics (Online) / 2021 / Cilt: 56 - Sayı: 5

Hemolytic Uremic Syndrome in Children

Bora GÜLHAN
Fatih ÖZALTIN
Pages
415–422
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Besides, therapeutic options that are based on the pathophysiology have been available for HUS patients.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Hemolytic uremic syndrome (HUS) is a thrombotic microangiopathy (TMA), mainly affecting the kidney.
📊
Key Findings & Data:The disease is characterized by microangiopathic hemolytic anemia, thrombocytopenia, and acute kidney injury.
💡
Conclusion & Impact:Besides, therapeutic options that are based on the pathophysiology have been available for HUS patients.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Özet

Hemolytic uremic syndrome (HUS) is a thrombotic microangiopathy (TMA), mainly affecting the kidney. The disease is characterized by microangiopathic hemolytic anemia, thrombocytopenia, and acute kidney injury. It is one of the most common causes of acute kidney injury in children. Under this umbrella, there are several different disorders: Shiga toxin-associated HUS, Streptococcus pneumoniae-associated HUS, and HUS associated with complement dysregulation. Several drugs and conditions may also cause HUS. There are many different classification systems, which have been developed during the history of the disease. In recent years, clinical and experimental studies have revealed abnormalities in different pathways beyond complement system. Besides, therapeutic options that are based on the pathophysiology have been available for HUS patients.

🔖

Cite This Article

GÜLHAN, B., ÖZALTIN, F. (2021). Hemolytic Uremic Syndrome in Children. Turkish archives of pediatrics (Online), Cilt: 56 - Sayı: 5, 415–422. https://ajindex.com/articles/143230

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (16)

  1. Fakhouri F, Zuber J, Frémeaux-Bacchi V, Loirat C. Haemolytic uraemic syndrome. Lancet. 2017
  2. 390(10095):681-696. [CrossRef] 2. Gasser C, Gautier E, Steck A, Siebenmann RE, Oechslin R. Hemolytic-uremic syndrome: bilateral necrosis of the renal cortex in acute acquired hemolytic anemia. Schweiz Med Wochenschr. 1955
  3. 85(38-39):905-909. 3. Loirat C, Frémeaux-Bacchi V. Atypical hemolytic uremic syndrome. Orphanet J Rare Dis. 2011
  4. [CrossRef] 4. Loirat C, Fakhouri F, Ariceta G, et al. An international consensus approach to the management of atypical hemolytic uremic syndrome in children. Pediatr Nephrol. 2016
  5. 31(1):15-39. [CrossRef] 5. Lemaire M, Noone D, Lapeyraque AL, Licht C, Frémeaux-Bacchi V. Inherited kidney complement diseases. Clin J Am Soc Nephrol. 2021
  6. 16(6):942-956. [CrossRef] 6. Ong KL, Apostal M, Comstock N, et al. Strategies for surveillance of pediatric hemolytic uremic syndrome: foodborne diseases Active Surveillance Network Foodnet, (2000-2007). Clin Infect Dis. 2012
  7. 54(suppl 5):S424-S431. [CrossRef] 7. Ruggenenti P, Remuzzi GA. German outbreak of hemolytic uremic syndrome. Lancet. 2011
  8. 378(9796):1057-1058. [CrossRef] 8. Petruzziello-Pellegrini TN, Yuen DA, Page AV, et al. The CXCR4/ CXCR7/SDF-1 pathway contributes to the pathogenesisof Shiga toxin-associated hemolytic uremic syndrome in humans and mice. J Clin Invest. 2012
  9. 122(2):759-776. [CrossRef] 9. George JN, Nester CM. Syndromes of thrombotic microangiopathy. N Engl J Med. 2014
  10. 371(7):654-666. [CrossRef] 10. Thurman JM, Marians R, Emlen W, et al. Alternative pathway of complement in children with diarrhea-associated hemolytic uremic syndrome. Clin J Am Soc Nephrol. 2009
  11. 4(12):1920-1924. [CrossRef] 11. Cody EM, Dixon BP. Hemolytic uremic syndrome. Pediatr Clin North Am. 2019
  12. 66(1):235-246. [CrossRef] 12. Salvadori M, Bertoni E. Update on hemolytic uremic syndrome: diagnostic and therapeutic recommendations. World J Nephrol. 2013
  13. 2(3):56-76. [CrossRef] 13. Walsh PR, Johnson S. Treatment and management of children with haemolytic uremic syndrome. Arch Dis Child. 2018
  14. 103(3):285-291. [CrossRef] 14. Ardissino G, Possenti I, Tel F, Testa S, Paglialonga F. Time to change the definition of hemolytic uremic syndrome. Eur J Intern Med. 2014
  15. 25(2):e29. [CrossRef] 15. Khalid M, Andreoli S. Extrarenal manifestations of the hemolytic uremic syndrome associated with Shiga toxin-producing Escherichia coli (STEC HUS). Pediatr Nephrol. 2019
  16. 34(12):2495-2507. [CrossRef] 16. Ardissino G, Tel F, Possenti